The pathophysiology of neurological toxicities secondary to immune checkpoint inhibitors (ICIs) is unknown. Various mechanisms have been proposed: activation of cytotoxic CD8 T cells, autoantibodies via activation of B cells and CD4 cells, non-specific inflammation through the production of pro-inflammatory cytokines, and complement activation.
The aim of this research is to characterise the pathophysiological mechanisms of neurotoxicities in cancer patients treated with ICIs.
Adult patient (aged ≥ 18 years)
Affiliated with a social security scheme
Express consent to participate in the study
Indication for lumbar puncture And
Contraindication or refusal to perform a lumbar puncture
Sample not suitable for research (volume of CSF collected for treatment >5 mL)
Corticosteroid therapy or other immunomodulatory treatment in progress (discontinued less than 15 days prior to inclusion)
Pregnant or breastfeeding women